SG11201907334QA - Therapeutic dendrimers - Google Patents
Therapeutic dendrimersInfo
- Publication number
- SG11201907334QA SG11201907334QA SG11201907334QA SG11201907334QA SG11201907334QA SG 11201907334Q A SG11201907334Q A SG 11201907334QA SG 11201907334Q A SG11201907334Q A SG 11201907334QA SG 11201907334Q A SG11201907334Q A SG 11201907334QA SG 11201907334Q A SG11201907334Q A SG 11201907334QA
- Authority
- SG
- Singapore
- Prior art keywords
- astrazeneca
- international
- starpharma
- cresent
- victoria
- Prior art date
Links
- 239000000412 dendrimer Substances 0.000 title abstract 4
- 229920000736 dendritic polymer Polymers 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/40—Polyamides containing oxygen in the form of ether groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/003—Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Prostheses (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461983P | 2017-02-22 | 2017-02-22 | |
| US201762488151P | 2017-04-21 | 2017-04-21 | |
| US201762591823P | 2017-11-29 | 2017-11-29 | |
| PCT/EP2018/054420 WO2018154004A1 (en) | 2017-02-22 | 2018-02-22 | Therapeutic dendrimers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907334QA true SG11201907334QA (en) | 2019-09-27 |
Family
ID=61386833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907334QA SG11201907334QA (en) | 2017-02-22 | 2018-02-22 | Therapeutic dendrimers |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10314920B2 (es) |
| EP (1) | EP3585441A1 (es) |
| JP (1) | JP7074761B2 (es) |
| KR (2) | KR20230093346A (es) |
| CN (2) | CN110312531A (es) |
| AU (1) | AU2018223149B2 (es) |
| BR (1) | BR112019016409A2 (es) |
| CA (1) | CA3053069A1 (es) |
| CL (1) | CL2019002240A1 (es) |
| CO (1) | CO2019009722A2 (es) |
| CR (1) | CR20190361A (es) |
| DO (1) | DOP2019000204A (es) |
| EC (1) | ECSP19056271A (es) |
| IL (1) | IL268648B (es) |
| JO (1) | JOP20190191A1 (es) |
| MX (1) | MX2019009442A (es) |
| NI (1) | NI201900088A (es) |
| PE (1) | PE20191660A1 (es) |
| PH (1) | PH12019501896A1 (es) |
| SG (1) | SG11201907334QA (es) |
| TW (1) | TWI773730B (es) |
| UA (1) | UA125655C2 (es) |
| WO (1) | WO2018154004A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN112543664A (zh) * | 2018-08-17 | 2021-03-23 | 阿斯利康(瑞典)有限公司 | 树枝状体配制品 |
| JP7550149B2 (ja) * | 2018-11-20 | 2024-09-12 | スターファーマ ピーティーワイ エルティーディー | 治療用デンドリマー |
| EP3965567B1 (en) | 2019-05-07 | 2023-07-05 | Syddansk Universitet | Mechanism for dispensing biological material |
| JP2022549680A (ja) * | 2019-09-26 | 2022-11-28 | スターファーマ ピーティーワイ エルティーディー | 治療用デンドリマー |
| US20210170040A1 (en) * | 2019-12-04 | 2021-06-10 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery |
| WO2021213492A1 (zh) * | 2020-04-24 | 2021-10-28 | 上海森辉医药有限公司 | 一类载药的大分子及其制备方法 |
| AU2021259877A1 (en) | 2020-04-24 | 2022-12-08 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome |
| WO2022007940A1 (zh) * | 2020-07-10 | 2022-01-13 | 江苏恒瑞医药股份有限公司 | 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用 |
| WO2022042583A1 (zh) | 2020-08-25 | 2022-03-03 | 上海森辉医药有限公司 | 载药的大分子及其制备方法 |
| WO2022040761A1 (en) * | 2020-08-31 | 2022-03-03 | Starpharma Pty Ltd | Dendrimer-drug conjugate |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4289872A (en) * | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US4410688A (en) * | 1981-04-29 | 1983-10-18 | Allied Corporation | Macromolecular highly branched homogeneous compound |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| PL2757099T3 (pl) | 2005-05-12 | 2018-02-28 | Abbvie Bahamas Limited | Promotory apoptozy |
| HUE031341T2 (hu) * | 2005-10-25 | 2017-07-28 | Starpharma Pty Ltd | Ellenõrzött sztöchiometriájú makromolekuláris vegyületek |
| JP5989294B2 (ja) | 2006-01-20 | 2016-09-07 | スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ | 修飾高分子 |
| WO2008017122A1 (en) * | 2006-08-11 | 2008-02-14 | Starpharma Pty Ltd | Polylysine dendrimer contrast agent |
| US8420067B2 (en) * | 2006-08-11 | 2013-04-16 | Starpharma Pty Ltd | Targeted polylysine dendrimer therapeutic agent |
| JP5366817B2 (ja) | 2006-11-15 | 2013-12-11 | ジェネンテック， インコーポレイテッド | アリールスルホンアミド化合物 |
| US9283302B2 (en) | 2011-12-16 | 2016-03-15 | Cormatrix Cardiovascular, Inc. | Extracellular matrix encasement structures and methods |
| WO2009036035A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| US8216549B2 (en) * | 2008-07-25 | 2012-07-10 | National Health Research Institutes | Method for making a ligand-quantum dot conjugate |
| BRPI0922771A2 (pt) | 2008-12-05 | 2018-11-06 | Abbott Lab | agentes indutores de apoptose seletivos para bcl-2 para o tratamento de câncer e doenças imunes |
| KR102001418B1 (ko) | 2009-05-26 | 2019-07-19 | 애브비 아일랜드 언리미티드 컴퍼니 | 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | Abbott Gmbh & Co Kg | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| US20120269721A1 (en) * | 2009-10-12 | 2012-10-25 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| EP2571496A4 (en) | 2010-05-05 | 2016-03-30 | Prolynx Llc | CONTROLLED RELEASE OF MEDICINE FROM DENIMERS |
| US8754190B2 (en) | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
| WO2011140392A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from solid supports |
| TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| JP6158177B2 (ja) * | 2011-06-06 | 2017-07-05 | スターファーマ・ピーティーワイ・リミテッド | 高分子 |
| US20160220689A1 (en) * | 2013-09-10 | 2016-08-04 | Starpharma Pty Ltd. | Macromolecules of dendrimer-platinum conjugates |
| WO2015184510A1 (en) * | 2014-06-06 | 2015-12-10 | Starpharma Pty Ltd | Dendrimer-drug conjugates |
| JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN112543664A (zh) * | 2018-08-17 | 2021-03-23 | 阿斯利康(瑞典)有限公司 | 树枝状体配制品 |
-
2017
- 2017-06-16 JO JOP/2019/0191A patent/JOP20190191A1/ar unknown
-
2018
- 2018-02-12 TW TW107105033A patent/TWI773730B/zh active
- 2018-02-20 US US15/899,892 patent/US10314920B2/en active Active
- 2018-02-22 UA UAA201909735A patent/UA125655C2/uk unknown
- 2018-02-22 CN CN201880012429.9A patent/CN110312531A/zh active Pending
- 2018-02-22 CN CN202311534590.1A patent/CN117582521A/zh active Pending
- 2018-02-22 CR CR20190361A patent/CR20190361A/es unknown
- 2018-02-22 EP EP18707681.5A patent/EP3585441A1/en active Pending
- 2018-02-22 AU AU2018223149A patent/AU2018223149B2/en active Active
- 2018-02-22 KR KR1020237019533A patent/KR20230093346A/ko active IP Right Grant
- 2018-02-22 KR KR1020197027415A patent/KR102544033B1/ko active IP Right Grant
- 2018-02-22 SG SG11201907334QA patent/SG11201907334QA/en unknown
- 2018-02-22 PE PE2019001564A patent/PE20191660A1/es unknown
- 2018-02-22 CA CA3053069A patent/CA3053069A1/en active Pending
- 2018-02-22 JP JP2019543376A patent/JP7074761B2/ja active Active
- 2018-02-22 MX MX2019009442A patent/MX2019009442A/es unknown
- 2018-02-22 BR BR112019016409A patent/BR112019016409A2/pt active Search and Examination
- 2018-02-22 WO PCT/EP2018/054420 patent/WO2018154004A1/en active Application Filing
-
2019
- 2019-04-05 US US16/376,419 patent/US10888624B2/en active Active
- 2019-08-06 EC ECSENADI201956271A patent/ECSP19056271A/es unknown
- 2019-08-08 CL CL2019002240A patent/CL2019002240A1/es unknown
- 2019-08-08 DO DO2019000204A patent/DOP2019000204A/es unknown
- 2019-08-12 IL IL268648A patent/IL268648B/en unknown
- 2019-08-15 PH PH12019501896A patent/PH12019501896A1/en unknown
- 2019-08-20 NI NI201900088A patent/NI201900088A/es unknown
- 2019-09-09 CO CONC2019/0009722A patent/CO2019009722A2/es unknown
-
2020
- 2020-11-11 US US17/095,043 patent/US11717574B2/en active Active
-
2023
- 2023-06-14 US US18/334,672 patent/US20240115716A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907334QA (en) | Therapeutic dendrimers | |
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201907742YA (en) | Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906417RA (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201908568XA (en) | Therapeutic compounds and methods | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201908065YA (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201909466RA (en) | Human anti-semaphorin 4d antibody | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases |